These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 9330064)

  • 1. Serum levels of soluble interleukin-2 receptor--a possible index of disease prognosis in systemic sclerosis.
    Lis A; Brzezińska-Wcisło L; Rubisz-Brzezińska J; Kulawik I
    Clin Exp Dermatol; 1997 Jan; 22(1):60-1. PubMed ID: 9330064
    [No Abstract]   [Full Text] [Related]  

  • 2. [Soluble receptors of cytokines in sera of patients with systemic sclerosis--clinical correlation].
    Lis AD; Brzezińska-Wcisło LA
    Wiad Lek; 2003; 56(11-12):532-6. PubMed ID: 15058159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Duration of Raynaud's phenomenon is negatively correlated with serum levels of interleukin 10 (IL-10), soluble receptor of interleukin 2 (sIL2R), and sFas in systemic sclerosis patients.
    Dziankowska-Bartkowiak B; Zalewska A; Sysa-Jedrzejowska A
    Med Sci Monit; 2004 May; 10(5):CR202-8. PubMed ID: 15114270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cartilage oligomeric matrix protein in systemic sclerosis.
    Yamamoto M; Takahashi H; Suzuki C; Naishiro Y; Yamamoto H; Imai K; Shinomura Y
    Rheumatology (Oxford); 2007 Dec; 46(12):1858-9. PubMed ID: 17895282
    [No Abstract]   [Full Text] [Related]  

  • 5. Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis.
    Hasegawa M; Sato S; Fujimoto M; Ihn H; Kikuchi K; Takehara K
    J Rheumatol; 1998 Feb; 25(2):308-13. PubMed ID: 9489824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical correlations of potential activity markers in systemic sclerosis.
    Becvár R; Stork J; Pesáková V; Stánová A; Hulejová H; Rysová L; Zatloukalová A; Zatloukal P; Jáchymová M; Pourová L
    Ann N Y Acad Sci; 2005 Jun; 1051():404-12. PubMed ID: 16126982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum levels of interleukin 15 in patients with rheumatic diseases.
    Suzuki J; Morimoto S; Amano H; Tokano Y; Takasaki Y; Hashimoto H
    J Rheumatol; 2001 Nov; 28(11):2389-91. PubMed ID: 11708407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostacyclin analogue iloprost influences endothelial cell-associated soluble adhesion molecules and growth factors in patients with systemic sclerosis: a time course study of serum concentrations.
    Rehberger P; Beckheinrich-Mrowka P; Haustein UF; Sticherling M
    Acta Derm Venereol; 2009; 89(3):245-9. PubMed ID: 19479119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levels of interleukin 12, a cytokine of type 1 helper T cells, are elevated in sera from patients with systemic sclerosis.
    Sato S; Hanakawa H; Hasegawa M; Nagaoka T; Hamaguchi Y; Nishijima C; Komatsu K; Hirata A; Takehara K
    J Rheumatol; 2000 Dec; 27(12):2838-42. PubMed ID: 11128673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Interleukin-2 and interleukin-6 in serum as markers of disease progression in systemic sclerosis].
    Lis A; Brzezińska-Wcisło L
    Pol Merkur Lekarski; 2001 Sep; 11(63):206-9. PubMed ID: 11761811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of serum hyaluronan levels in systemic sclerosis: association with disease severity.
    Yoshizaki A; Iwata Y; Komura K; Hara T; Ogawa F; Muroi E; Takenaka M; Shimizu K; Hasegawa M; Fujimoto M; Sato S
    J Rheumatol; 2008 Sep; 35(9):1825-9. PubMed ID: 18688912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble interleukin-2 receptor, intercellular adhesion molecule-1 and interleukin-10 serum levels in patients with melanoma.
    Boyano MD; Garcia-Vázquez MD; López-Michelena T; Gardeazabal J; Bilbao J; Cañavate ML; Galdeano AG; Izu R; Díaz-Ramón L; Raton JA; Díaz-Pérez JL
    Br J Cancer; 2000 Oct; 83(7):847-52. PubMed ID: 10970683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum IL-15 in patients with early systemic sclerosis: a potential novel marker of lung disease.
    Wuttge DM; Wildt M; Geborek P; Wollheim FA; Scheja A; Akesson A
    Arthritis Res Ther; 2007; 9(5):R85. PubMed ID: 17784951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of cardiac laboratory markers in patients with systemic sclerosis.
    Montagnana M; Lippi G; Volpe A; Salvagno GL; Biasi D; Caramaschi P; Cesare Guidi G
    Clin Biochem; 2006 Sep; 39(9):913-7. PubMed ID: 16713594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum CCL13 levels in patients with systemic sclerosis and controls.
    Gambichler T; Yilmaz E; Höxtermann S; Kolios A; Moritz R; Bechara FG; Kreuter A
    Br J Dermatol; 2011 Jul; 165(1):216-8. PubMed ID: 21428976
    [No Abstract]   [Full Text] [Related]  

  • 16. [Level of soluble tumor necrosis factor receptor type I in patients with systemic scleroderma].
    Alekperov RT; Timchenko AV; Samsonov MIu; Guseva NG; Nasonov EL
    Ter Arkh; 2004; 76(5):11-5. PubMed ID: 15230124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with spontaneous regression of skin sclerosis.
    Matsushita T; Hasegawa M; Hamaguchi Y; Takehara K; Sato S
    J Rheumatol; 2006 Feb; 33(2):275-84. PubMed ID: 16465658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High circulating levels of VEGF-C suggest abnormal lymphangiogenesis in systemic sclerosis.
    Chitale S; Al-Mowallad AF; Wang Q; Kumar S; Herrick A
    Rheumatology (Oxford); 2008 Nov; 47(11):1727-8. PubMed ID: 18820309
    [No Abstract]   [Full Text] [Related]  

  • 19. [TNF-alpha and soluble interleukin-2 receptor and glomerular sclerosis in primary nephrotic syndrome in children].
    Pogan A; Sancewicz-Pach K; Miezyński W
    Wiad Lek; 2005; 58 Suppl 1():39-44. PubMed ID: 16060083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The interleukin-1, interleukin-2, interleukin-6 and tumour necrosis factor alpha serological levels in localised and systemic sclerosis.
    Alecu M; Geleriu L; Coman G; Gălăţescu L
    Rom J Intern Med; 1998; 36(3-4):251-9. PubMed ID: 10822522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.